SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 755.75+2.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (2073)3/22/2017 11:38:09 AM
From: Miljenko Zuanic  Read Replies (1) of 3559
 
After UK early marketing approval, Le Trait facility failure were less likely, but not completely eliminated. Preemptive IP disagreement with IMNX early Dupi-related patents, well, even if failed, will not hold beyond 2018/2020...so not a big deal for few % royalty.

So, early marketing success with Dupi is very important at this point. Asthma and other indications are equally important as well, ...there are good biology works that Dupi may be "BEST" play for allergic indications.

Finger crossed for next few weeks.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News